

# Apomorphine and Other Dopaminomimetics

Volume 2  
CLINICAL PHARMACOLOGY

Editors

Giovanni Umberto Corsini  
Gian Luigi Gessa

# Apomorphine and Other Dopaminomimetics

## Volume 2 Clinical Pharmacology

Editors

Giovanni Umberto Corsini, M.D.

Gian Luigi Gessa, M.D.

*Institute of Pharmacology*

*University of Cagliari*

*Cagliari, Italy*



Raven Press ■ New York

Raven Press, 1140 Avenue of the Americas, New York, New York 10036

---

© 1981 by Raven Press Books, Ltd. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher.

Made in the United States of America

International Standard Book Number 0-89004-667-0

Library of Congress Catalog Number 81-40610

---

Great care has been taken to maintain the accuracy of the information contained in the volume. However, Raven Press cannot be held responsible for errors or for any consequences arising from the use of the information contained herein.

Materials appearing in this book prepared by individuals as part of their official duties as U.S. Government employees are not covered by the above-mentioned copyright.

## Preface

Apomorphine was discovered in 1869 as a by-product of morphine, and has for many years been considered primarily for its emetic properties—in spite of its ability to produce other peripheral and central actions. In addition to its morphine-like actions, apomorphine exerts cardiovascular and hypotensive effects, selectively alters gastric motility, and induces a variety of stereotyped behaviors. Increased attention was given to apomorphine when it was found to have sedative properties, which made it a valuable aid in treating agitated patients, and in 1951 when Schwab described its usefulness in the treatment of Parkinson's disease.

The popularity of apomorphine, however, is linked to that of dopamine, which has also been considered a "cinderella" drug among neurotransmitters. The relationship of apomorphine to dopamine was clarified significantly by Ernst in 1967, whose studies indicated the existence of structural similarities between the two drugs, thus explaining the dopaminergic nature of apomorphine's effects. Apomorphine has since been known as a specific tool for the study of dopamine function in animals and humans. Research focusing in this direction has led to the development of several analogs with dopaminergic properties and of newly synthesized agonists, which have proven to be valuable pharmacological agents with a myriad of useful therapeutic applications.

*Apomorphine and Other Dopaminomimetics* is a two-volume set which organizes the material in this field into basic and clinical research. *Volume 1: Basic Pharmacology* is a comprehensive treatise on various aspects of the use of apomorphine and related dopaminomimetics to disclose central and peripheral roles of dopamine in regulating physiological functions such as motor activity, sleep, wakefulness, food intake, hormonal control, blood pressure, and diuresis. *Volume 2: Clinical Pharmacology* deals with the clinical aspects of dopamine agonists in relation to schizophrenic and affective disorders, Parkinson's disease and dyskinesias, sleep, pituitary hormone interactions, aging, and arterial pressure control.

These two volumes represent the establishment of apomorphine as an invaluable tool in basic and clinical research in the neurosciences, and will be of interest to pharmacologists as well as neuroscientists.

## Acknowledgments

This volume is based on presentations from a symposium entitled "Clinical Pharmacology of Apomorphine and Other Dopaminomimetics," held in Villasimius, Italy in September 1980. We would like to thank the Fidia Research Laboratories of Abano Terme (Italy), who were the principal sponsors of the congress, and also Sandoz Ltd. of Basel (Switzerland) and Milan (Italy) for their contribution. Further, for the expert organization and smooth running of the symposium we wish to thank Dr. Cristina Schirato of Fidia Research Laboratories, and Miss Anne Farmer, whose assistance was also greatly appreciated in the publishing of this book.

The popularity of apomorphine, however, is linked to that of dopamine, which has also been considered a "cinderella" drug among neurotransmitters. The relationship of apomorphine to dopamine was clarified significantly by Elmer in 1967, whose studies indicated the existence of structural similarities between the two drugs, thus explaining the dopaminergic nature of apomorphine's effects. Apomorphine has since been known as a specific tool for the study of dopamine function in animals and humans. Research focusing in this direction has led to the development of several analogs with dopaminergic properties and of newly synthesized agonists, which have proved to be valuable pharmacological agents with a myriad of useful therapeutic applications.

Apomorphine and Other Dopaminomimetics is a two-volume set which organizes the material in this field into basic and clinical research. Volume 1: Basic Pharmacology is a comprehensive treatise on various aspects of the use of apomorphine and related dopaminomimetics to disclose central and peripheral roles of dopamine in regulating physiological functions such as motor activity, sleep, wakefulness, food intake, hormonal control, blood pressure, and diuresis. Volume 2: Clinical Pharmacology deals with the clinical aspects of dopamine agonists in relation to schizophrenic and affective disorders, Parkinson's disease, and dyskinesias, sleep, pituitary hormone interactions, aging, and arterial pressure control. These two volumes represent the establishment of apomorphine as an invaluable tool in basic and clinical research in the neurosciences, and will be of interest to pharmacologists as well as neuroscientists.

# Contributors

## **M. Ackenheil**

*Psychiatrische Klinik der Universität München  
Nussbaumstrasse 7  
8000 München, Germany*

## **C. Adani**

*Department of Human Physiology  
University of Modena  
Via Campi 287  
41100 Modena, Italy*

## **Y. Agid**

*Clinique de Neurologie et Neuropsychologie  
Hôpital de la Salpêtrière  
91, Boulevard de l'Hôpital  
75634 Paris, Cedex 13 France*

## **L. F. Agnati**

*Department of Human Physiology  
University of Modena  
Via Campi 287  
41100 Modena, Italy*

## **A. Agnoli**

*I Neurologic Clinica  
University of Roma  
00100 Rome, Italy*

## **M. G. Albizzati**

*Department of Neurology and Pharmacology  
University of Milan  
Bassini Hospital  
20092 Cinisello Balsamo, Italy*

## **C. Aldinio**

*Department of Biochemistry  
Fidia Research Laboratories  
35031 Abano Terme, Italy*

## **S. Algeri**

*Mario Negri Institute for Pharmacological Research  
Via Eritrea 62  
20156 Milan, Italy*

## **B. Angrist**

*Department of Psychiatry  
New York University School of Medicine  
550 First Avenue  
New York, New York 10016*

## **Gill Anzelark**

*Department of Neurology  
Institute of Psychiatry  
London SE5 8AF, United Kingdom*

## **T. Asano**

*Department of Neurochem.  
New York University Medical Center  
550 First Avenue  
New York, New York 10016*

## **M. Baldassare**

*Neurologic Clinic  
University Institute of Medicine  
67100 L'Aquila, Italy*

## **C. Barale**

*Institute of Pharmacology  
Faculty of Medicine  
University of Catania  
V. le A. Doria 6  
95125 Catania, Italy*

## **S. Bassi**

*Department of Neurology and Pharmacology  
University of Milan  
Bassini Hospital  
20092 Cinisello Balsamo, Italy*

## **Judith E. Beach**

*Department of Obstetrics, Gynecology, and Reproductive Sciences  
University of California School of Medicine  
San Francisco, California 94143*

## **F. Benfenati**

*Department of Human Physiology  
University of Modena  
Via Campi 287  
41100 Modena, Italy*

## **F. Bernardi**

*Department of Clinical Pharmacology  
University of Cagliari  
Via Porcell 4  
09100 Cagliari, Italy*

## **P. Bernardi**

*Department of Human Physiology  
University of Modena  
Via Campi 287  
41100 Modena, Italy*

## **A. Bocchetta**

*Department of Clinical Pharmacology  
University of Cagliari  
Via Porcell 4  
09100 Cagliari, Italy*



**M. Boccuni**

Department of Clinical Pharmacology  
University of Florence  
V. le Morgagni 85  
50134 Florence, Italy

**Jacques R. Boissier**

Centre de Recherches Roussel-Uclaf 102  
111 route de Noisy  
93230 Romainville, France

**C. L. E. Broekkamp**

Biology Department  
LERS  
Synthelabo  
58, rue de la Glacière  
F75013 Paris, France

**William E. Bunney, Jr.**

Section on Psychobiology  
Biological Psychiatry Branch  
National Institute of Mental Health  
Building 10, Room 3s239  
9000 Rockville Pike  
Bethesda, Maryland 20205

**Richard S. Burns**

Experimental Therapeutics Branch  
National Institute of Neurological and Commu-  
nicative Disorders and Stroke  
Room 6D20, Clinical Center  
National Institutes of Health  
Bethesda, Maryland 20205

**Donald B. Calne**

Experimental Therapeutics Branch  
National Institute of Neurological and Commu-  
nicative Disorders and Stroke  
Room 6D20, Clinical Center  
National Institutes of Health  
Bethesda, Maryland 20205

**G. Calderini**

Department of Biochemistry  
Fidia Research Laboratories  
35031 Abano Terme, Italy

**M. Capelli**

Centralized Laboratory  
St. Orsola Hospital  
Bologna, Italy

**P. L. Canonico**

Institute of Pharmacology  
Faculty of Medicine  
University of Catania  
V. le A. Doria 6  
95125 Catania, Italy

**F. Cathala**

Biology Department  
LERS  
Synthelabo  
58, rue de la Glacière  
F75013 Paris, France

**T. N. Chase**

Experimental Therapeutics Branch  
National Institute of Neurological and Commu-  
nicative Disorders and Stroke  
National Institutes of Health  
Bethesda, Maryland 20205

**Jin K. Chun**

University of Virginia School of Medicine  
Charlottesville, Virginia 22908

**C. Cianchetti**

Department of Child Neurology and Psychiatry  
University of Cagliari  
Cagliari 09100, Italy

**G. Clementi**

Institute of Pharmacology  
Faculty of Medicine  
University of Catania  
V. le A. Doria 6  
95125 Catania, Italy

**V. Cocchi**

Centralized Laboratory  
St. Orsola Hospital  
Bologna, Italy

**G. U. Corsini**

Department of Clinical Pharmacology  
University of Cagliari  
Via Porcell 4  
09100 Cagliari, Italy

**F. Crews**

Department of Pharmacology  
University of Florida College of Medicine  
Gainesville, Florida 32610

**Michael Cronin**

University of Virginia School of Medicine  
Charlottesville, Virginia 22908

**Neal R. Cutler**

Section on Psychobiology  
Biological Psychiatry Branch  
National Institute of Mental Health  
Building 10, Room 3S239  
9000 Rockville Pike  
Bethesda, Maryland 20205

**John M. Davis**

*Illinois State Psychiatric Institute  
1601 West Taylor Street  
Chicago, Illinois 60612*

**E. G. DeFraites**

*Department of Psychiatry  
Maryland Psychiatric Research Center  
University of Maryland  
Baltimore, Maryland 21228*

**S. Del Roscio**

*Neurologic Clinic  
University Institute of Medicine  
67100 L'Aquila, Italy*

**M. Del Zompo**

*Department of Clinical Pharmacology  
University of Cagliari  
Via Porcell 4  
09100 Cagliari, Italy*

**A. Destee**

*Clinique de Neurologie  
CHU  
Lille, France*

**F. Drago**

*Institute of Pharmacology  
Faculty of Medicine  
University of Catania  
V. le A. Doria 6  
95125 Catania, Italy*

**Catherine Euvrard**

*Centre de Recherches Roussel-  
Uclaf 102  
111 route de Noisy  
93230 Romainville, France*

**M. Fanciullacci**

*Department of Clinical Pharmacology  
University of Florence  
V. le Morgagni 85  
50134 Florence, Italy*

**L. Frattola**

*Department of Neurology and Pharmacology  
University of Milan  
Bassini Hospital  
20092 Cinisello Balsamo, Italy*

**P. Fresia**

*Ravizza Research Laboratories  
Muggiò  
20100 Milan, Italy*

**A. Gaiti**

*Department of Biochemistry  
University of Perugia  
06100 Perugia, Italy*

**G. L. Gessa**

*Institute of Pharmacology  
University of Cagliari  
Via Porcell 4  
09100 Cagliari, Italy*

**J. Christian Gillin**

*Biological Psychiatry Branch  
IRP, National Institute of Mental Health  
Bethesda, Maryland 20205*

**M. D. Gotts**

*Department of Psychiatry  
Maryland Psychiatric Research Center  
University of Maryland  
Baltimore, Maryland 21228*

**C. G. Gottfries**

*Department of Psychiatry and Neurochemistry  
St. Jorgens Hospital  
University of Goteborg  
422 03 Hisings Backa, Sweden*

**M. Goldstein**

*Department of Neurochemistry  
New York University Medical Center  
550 First Avenue  
New York, New York 10016*

**Leo E. Hollister**

*Department of Psychiatry and Pharmacology  
Stanford University School of Medicine  
Palo Alto, California 94304*

**A. Illas**

*Department of Neurology  
Faculty of Medicine  
Athens, Greece*

**David C. Jimerson**

*Section on Psychobiology  
Biological Psychiatry Branch  
National Institute of Mental Health  
9000 Rockville Pile  
Building 10, Room 3S239  
Bethesda, Maryland 20205*

**Michel Jouvett**

*Department of Experimental Medicine  
Université Claude-Bernard  
Lyon, France*



**Farouk Karoum**

Adult Psychiatry Branch  
Division of Special Mental Health Research  
Intramural Research Program  
National Institute of Mental Health  
St. Elizabeth's Hospital  
Washington, D.C. 20032

**Bernard Kerdelhue**

Laboratoire Hormones Polypeptidiques  
CNRS  
91190 Gif-sur-Yvette, France

**Joel E. Kleinman**

Adult Psychiatry Branch  
Division of Special Mental Health Research  
Intramural Research Program  
National Institute of Mental Health  
St. Elizabeth's Hospital  
Washington, D.C. 20032

**S. Lal**

Department of Psychiatry  
Montreal General Hospital  
Montreal, Quebec, Canada H3G 1A4

**F. Lhermitte**

Clinique de Neurologie et Neuropsychologie  
Hôpital de la Salpêtrière  
91, Boulevard de l'Hôpital  
75634 Paris, Cedex 13, France

**K. G. Lloyd**

Biology Department  
LERS  
Synthélabo  
58, rue de la Glacière  
F75013 Paris, France

**Ivan S. Login**

University of Virginia School of Medicine  
Charlottesville, Virginia 22908

**G. Lomuscio**

Mario Negri Institute for Pharmacological  
Research  
Via Eritrea 62  
20156 Milan, Italy

**Robert M. MacLeod**

University of Virginia School of Medicine  
Charlottesville, Virginia 22908

**G. Marrosu**

Department of Child Neurology and Psychiatry  
University of Cagliari  
Via Ospedale  
09100 Cagliari, Italy

**C. D. Marsden**

University Department of Neurology  
Institute of Psychiatry  
Denmark Hill  
London SE5, United Kingdom

**C. Masala**

Clinic of Neurology  
University of Cagliari  
Via Ospedale  
09100 Cagliari, Italy

**Brian Meldrum**

Department of Neurology  
Institute of Psychiatry  
London SE5 8AF, United Kingdom

**S. Michelacci**

Department of Clinical Pharmacology  
University of Florence  
V. le Morgagni 85  
50134 Florence, Italy

**Egidio A. Moja**

Institute of Neurology  
University of Cagliari  
09100 Cagliari, Italy

**F. Nicoletti**

Institute of Pharmacology  
Faculty of Medicine  
University of Catania  
V. le A. Doria 6  
95125 Catania, Italy

**P. Olivari**

Department of Child Neurology and Psychiatry  
University of Cagliari  
Via Ospedale  
09100 Cagliari, Italy

**N. Palesse**

Neurologic Clinic  
University Institute of Medicine  
67100 L'Aquila, Italy

**P. Passouant**

Service de Physiopathologie des Maladies Ner-  
veuses  
Université de Montpellier  
Boulevard Henri IV  
Montpellier, France

**Richard L. Perryman**

University of Virginia School of Medicine  
Charlottesville, Virginia 22908

**M. P. Piccardi**

Department of Clinical Pharmacology  
University of Cagliari  
Via Porcell 4  
09100 Cagliari, Italy

**G. F. Pitzalis**

Department of Clinical Pharmacology  
University of Cagliari  
Via Porcell 4  
09100 Cagliari, Italy

**P. Pollak**

Clinique de Neurologie  
CHU  
Grenoble, France

**F. Ponzio**

Mario Negri Institute for Pharmacological  
Research  
Via Eritrea 62  
20156 Milan, Italy

**Robert M. Post**

Section on Psychobiology  
Biological Psychiatry Branch  
National Institute of Mental Health  
Building 10, Room 3S239  
9000 Rockville Pike  
Bethesda, Maryland 20205

**Steven G. Potkin**

Adult Psychiatry Branch  
Division of Special Mental Health Research  
Program  
Intramural Research Program  
National Institute of Mental Health  
St. Elizabeth's Hospital  
Washington, D.C. 20032

**A. Prato**

Institute of Pharmacology  
Faculty of Medicine  
University of Catania  
V. le A. Doria 6  
95125 Catania, Italy

**N. Quinn**

Department of Neurology  
Institute of Psychiatry  
De Crespigny Park  
London SE5 8AF, United Kingdom

**J. Rotrosen**

Department of Psychiatry  
New York University School of Medicine  
550 First Avenue  
New York, New York 10016

**S. Ruggieri**

Neurologic Clinic  
University Institute of Medicine  
67100 L'Aquila, Italy

**U. Scapagnini**

Institute of Pharmacology  
University of Catania  
V. le A. Doria 6  
95125 Catania, Italy

**Martin H. Schaeffer**

Department of Psychiatry  
University of Chicago  
Chicago, Illinois 60601

**F. Sicuteri**

Department of Clinical Pharmacology  
University of Florence  
V. le Morgagni 85  
50134 Florence, Italy

**J. L. Signoret**

Clinique de Neurologie et Neuropsychologie  
Hôpital de la Salpêtrière  
91, Boulevard de l'Hôpital  
75634 Paris, Cedex 13, France

**Robert C. Smith**

Texas Research Institute for Mental Sciences  
Houston, Texas 77025

**N. Sitaram**

Biological Psychiatry Branch  
IRP, National Institute of Mental Health  
Bethesda, Maryland 20205

**David M. Stoff**

Adult Psychiatry Branch  
Division of Special Mental Health Research  
Intramural Research Program  
National Institute of Mental Health  
St. Elizabeth's Hospital  
Washington, D.C. 20032

**Carol A. Tamminga**

Department of Psychiatry  
Maryland Psychiatric Research Center  
University of Maryland  
Baltimore, Maryland 21228

**Michael O. Thorner**

University of Virginia School of Medicine  
Charlottesville, Virginia 22908

**G. Toffano**

Department of Biochemistry  
Fidia Research Laboratories  
35031 Abano Terme, Italy

**M. Trabucchi**

*Department of Neurology and Pharmacology  
University of Milan  
Bassini Hospital  
20092 Cinisello Balsamo, Italy*

**D. P. van Kammen**

*Biological Psychiatry Branch  
IRP, National Institute of Mental Health  
Bethesda, Maryland 20205*

**Richard I. Weiner**

*Department of Obstetrics, Gynecology and  
Reproductive Sciences  
University of California School of Medicine  
San Francisco, California 94143*

**P. Worms**

*Biology Department*

**LERS**

*Synthélabo  
58, rue del la Glacière  
F75013 Paris, France*

**Richard J. Wyatt**

*Adult Psychiatry Branch  
Division of Special Mental Health Research  
Intramural Research Program  
National Institute of Mental Health  
St. Elizabeth's Hospital  
Washington, D.C. 20032*

**I. Zini**

*Department of Human Physiology  
University of Modena  
Via Campi 287  
41100 Modena, Italy*

APOMORPHINE AND OTHER DOPAMINOMIMETICS

---

**APOMORPHINE AND OTHER DOPAMINOMIMETICS** Volume 2: Clinical Pharmacology

**Volume 2: Clinical Pharmacology**

# APOMORPHINE AND OTHER DOPAMINOMIMETICS

---

Volume 1: Basic Pharmacology

Volume 2: Clinical Pharmacology

# Contents

## Volume 2: Clinical Pharmacology

### Clinical Aspects of Dopamine Agonists

#### 1 Clinical Studies with Apomorphine

*S. Lal*

#### 13 Behavioural Effects of Apomorphine in Man: Dopamine Receptor Implications *G. U. Corsini, M. P. Piccardi, A. Bocchetta, F. Bernardi, and M. Del Zompo*

#### 25 Dopamine Agonists in Reflex Epilepsy

*Brian Meldrum and Gill Anlezark*

### Schizophrenia and Affective Disorders

#### 33 Dopaminergic and Nondopaminergic Elements in Schizophrenia

*B. Angrist and J. Rotrosen*

#### 39 Phenylethylamine, Dopamine, and Norepinephrine in Schizophrenia

*Richard J. Wyatt, Egidio A. Moja, Farouk Karoum, David M. Stoff, Steven G. Potkin, and Joel E. Kleinman*

#### 45 Effects of Apomorphine on Schizophrenia

*John M. Davis, Carol Tamminga, Martin H. Schaeffer, and Robert C. Smith*

#### 49 Apomorphine and *N-n*-propylnorapomorphine in the Treatment of Schizophrenia

*C. A. Tamminga, E. G. DeFraites, M. D. Gotts, and T. N. Chase*

#### 57 Experiences with Dopamine Agonists in Depression and Schizophrenia

*Leo E. Hollister*

#### 65 Antipsychotic Effects of Apomorphine: A Retrospective Study

*M. Del Zompo, G. F. Pitzalis, F. Bernardi, A. Bocchetta, and G. U. Corsini*

#### 77 Dopamine Agonists in Affective Illness: Implications for Underlying Receptor Mechanisms

*Robert M. Post, Neal R. Cutler, David C. Jimerson, and William E. Bunney, Jr.*

### Parkinson's Disease and Dyskinesias

#### 93 Treatment of Parkinsonism with Artificial Dopaminomimetics: Pharmacokinetic Considerations

*Richard S. Burns and Donald B. Calne*

#### 107 The Treatment of Parkinson's Disease with Dopaminergic Agonists in Combination with Domperidone

*Y. Agid, N. Quinn, P. Pollack, A. Illas, A. Destee, J. L. Signoret, and F. Lhermitte*



- 117 Piribedil and Parkinson's Disease: Protection of Peripheral Side-Effects by Domperidone  
*A. Agnoli, M. Baldessarre, S. Del Roscio, N. Palesse, and S. Ruggieri*
- 123 Animal Models for the Prediction and Prevention of Dyskinesias Induced by Dopaminergic Drugs  
*K. G. Lloyd, C. L. E. Broekkamp, F. Cathala, P. Worms, M. Goldstein, and T. Asano*
- 135 Estrogen Control of DA-Receptor Related Dyskinesias  
*Catherine Euvrard and Jacques R. Boissier*
- 145 Dyskinesia, Dystonia, and Dopaminergic System: Effect of Apomorphine and Ergot Alkaloids  
*L. Frattola, M. G. Albizzati, S. Bassi, and M. Trabucchi*

### **Dopamine in Sleep Mechanisms**

- 153 Dopamine and Sleep—A Neurophysiologist's Introduction  
*Michel Jouvet*
- 157 What is the Role of Dopamine in the Regulation of Sleep-Wake Activity?  
*J. Christian Gillin, D. P. van Kammen, R. M. Post, N. Sitaram, R. J. Wyatt, and W. E. Bunney, Jr.*
- 165 Effect on Sleep of Dopaminergic Agonists  
*P. Passouant*
- 169 Sleep Pattern Modifications by Dopamine Agonists in Man  
*C. Cianchetti, C. Masala, P. Olivari, G. Marrosu, and G. L. Gessa*
- 183 Dopaminergic Receptor Modulation and Sleep Induction  
*M. Trabucchi, M. G. Albizzati, S. Bassi, and L. Frattola*

### **Dopamine and Pituitary Hormone Interactions**

- 187 Characterization of Anterior Pituitary Membrane and Cytosol Dopamine Receptors  
*Richard I. Weiner, Judith E. Beach, and Bernhard Kerdelhue*
- 195 Effects of Apomorphine on Inhibitory and Excitatory DA Receptors on Lactotropes  
*U. Scapagnini, P. L. Canonico, F. Drago, G. Clementi, A. Prato, C. Barale, and F. Nicoletti*
- 203 Dopaminergic Drugs in the Treatment of Prolactin Disorders  
*Michael O. Thorner, Richard L. Perryman, Michael Cronin, Ivan S. Login, Jin K. Chun, and Robert M. MacLeod*
- 215 Biochemical Effects of Apomorphine: Contribution to Schizophrenia Research  
*M. Ackenheil*

### **Aging and Neuronal Transmission**

- 225 Catecholamines and Adaptive Mechanisms in Senescent Rats  
*S. Algeri, G. Calderini, G. Lomuscio, G. Toffano, and F. Ponzio*
- 235 Aging and Information Processing  
*G. Calderini, C. Adinio, F. Crews, A. Gaiti, U. Scapagnini, S. Algeri, F. Ponzio, and G. Toffano*

- 243 Levels of Monoamines, Monoamine Metabolites, and Activity in Related Enzyme Systems Correlated to Normal Aging and in Patients with Dementia of Alzheimer Type  
*C. G. Gottfries*

### Peripheral Actions of Dopamine Agonists

- 251 Possible Role of Dopamine Receptors in the Control of Arterial Blood Pressure and Hormone Secretion in Normals and Hypertensive Patients: A Study with Sulpiride Isomers  
*L. F. Agnati, P. Bernardi, F. Benfenati, C. Adani, M. Capelli, V. Cocchi, I. Zini, and P. Fresia*
- 267 Impairment of Postural Reflex in Migraine: Possible Role of Dopamine Receptors  
*M. Boccuni, M. Fanciullacci, S. Michelacci, and F. Sicuteri*
- 275 Subject Index

# Contents

## Volume 1: Basic Pharmacology

### Introductory Issues

- 1 Historical Highlights of the Chemistry, Pharmacology, and Early Clinical Uses of Apomorphine  
*John L. Neumeyer, Samarthji Lal, and Ross J. Baldessarini*
- 19 Peptides and the Basal Ganglia  
*F. Jolicoeur, D. Rondeau, S. St.-Pierre, F. Rioux, and A. Barbeau*

### Basic Research on Dopaminergic Transmission

- 27 The Anatomical Basis for Feedback and Feedforward in the Striatonigral System  
*Valerie B. Domesick*
- 41 Substantia Nigra as an Efferent Station for Dopaminergic Behavioural Syndromes Arising in the Striatum  
*G. Di Chiara, M. Morelli, A. Imperato, and M. L. Porceddu*
- 65 The Coexistence of Dopamine and a CCK-Like Peptide in a Subpopulation of Midbrain Neurons: Immunocytochemical and Electrophysiological Studies  
*L. R. Skirboll, T. Hokfelt, A. A. Grace, D. W. Hommer, J. F. Rehfeld, K. Markey, M. Goldstein, and B. S. Bunney*
- 79 Effects of Opiates on Dopamine Release in the Cat Caudate Nucleus *In Vivo*  
*M. F. Chesselet, A. Chéramy, T. D. Reisine, and J. Glowinski*
- 85 Are Apomorphine, Bromocriptine, and the Methylxanthines Agonists at the Same Dopamine Receptor?  
*Urban Ungerstedt, Mario Herrera-Marschitz, and Miguel Casas Brugue*
- 95 Dopamine Receptor: A Unique Site with Multiple Postsynaptic Localization  
*Pierre Laduron*
- 105 New Evidence for Dopamine Receptors in Synaptosomes Controlling Dopamine Synthesis  
*A. H. Tissari and G. L. Gessa*
- 117 Brain Dopamine and Premature Ejaculation: Results of Treatment with Dopamine Antagonists  
*P. Falaschi, A. Rocco, G. De Giorgio, G. Frajese, W. Fratta, and G. L. Gessa*
- 123 Do Presynaptic Dopamine Autoreceptors Exist?  
*Franca Cerrito, Guido Maura, and Maurizio Raiteri*
- 133 Opposite Changes in DA-Autoreceptors Sensitivity Induced by Chronic Antidepressants and Neuroleptics  
*G. Serra, A. Argiolas, and G. L. Gessa*